Outcomes, problems and quality of life with the implantable cardioverter defibrillator

S S Reid1, S McKinley, S Nagy

  • 1Cooperative Research Centre for Cardiac Technology, Sydney, Australia.

Insights

Most implantable cardioverter defibrillator (ICD) recipients report good quality of life (QOL), though it decreases after experiencing defibrillator shocks. Patients desire more education and support during ICD insertion, which nurses could provide.

Area of Science:

  • Cardiology
  • Medical Devices
  • Patient Outcomes

Background:

  • The implantable cardioverter defibrillator (ICD) is a critical device for managing life-threatening cardiac arrhythmias.
  • Assessing patient-reported outcomes, including quality of life (QOL), is essential for understanding the real-world impact of ICD therapy.

Purpose of the Study:

  • To evaluate the quality of life (QOL) and identify challenges faced by recipients of implantable cardioverter defibrillators (ICDs).
  • To understand patient satisfaction and information needs regarding ICDs.

Main Methods:

  • A survey was conducted among implantable cardioverter defibrillator (ICD) recipients.
  • Data collected included quality of life scores, experiences with defibrillator shocks, resumption of daily activities, and information sources.

Main Results:

  • The average QOL score was 6.4 out of 10, significantly lower for patients who received shocks (p < 0.05).
  • 54% of patients reported experiencing at least one shock.
  • 72% resumed usual daily activities, and 76% resumed driving; 96% would recommend the ICD to others.

Conclusions:

  • Most ICD recipients experience a good quality of life (QOL), but this is negatively impacted by defibrillator shocks.
  • While patients generally gain understanding of living with an ICD, there is a significant need for enhanced education and support at the time of device implantation.
  • Nurses are identified as a key resource to provide this needed education and support to ICD recipients.

Related Concept Videos

Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...